Vir Biotechnology (VIR) Expected to Announce Earnings on Wednesday

Vir Biotechnology (NASDAQ:VIR) is expected to be releasing its earnings data after the market closes on Wednesday, February 26th. Analysts expect Vir Biotechnology to post earnings of ($0.85) per share and revenue of $8.14 million for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Vir Biotechnology Stock Down 2.3 %

NASDAQ:VIR opened at $9.57 on Monday. The stock’s 50 day moving average price is $9.31 and its 200 day moving average price is $8.48. The company has a market capitalization of $1.32 billion, a PE ratio of -2.44 and a beta of 0.64. Vir Biotechnology has a 52-week low of $6.56 and a 52-week high of $14.45.

Insider Activity at Vir Biotechnology

In other Vir Biotechnology news, Director Vicki L. Sato sold 10,960 shares of the business’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total transaction of $137,219.20. Following the sale, the director now directly owns 1,312,391 shares in the company, valued at approximately $16,431,135.32. The trade was a 0.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director George A. Scangos sold 10,964 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the sale, the director now owns 708,295 shares in the company, valued at approximately $6,948,373.95. The trade was a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,562 shares of company stock worth $259,693 over the last three months. 15.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Leerink Partners increased their price objective on Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Barclays lowered their target price on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. JPMorgan Chase & Co. lifted their target price on Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research note on Thursday, January 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, January 31st. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Vir Biotechnology currently has an average rating of “Moderate Buy” and a consensus target price of $34.83.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).